PRQR ProQR Therapeutics N.V.

NASDAQ
$2.07

ProQR Therapeutics N.V. (PRQR) is expected to report earnings on November 12, 2026, before the market open. The consensus earnings estimate is a loss of $0.11 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +8.4% since its last earnings release on August 13, 2026.

ProQR Therapeutics N.V. Beat Consensus Estimates
Thursday, August 13, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 7:00 AM ET
Earnings Whisper
-
vs ($0.11)
Rev est $5.35M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.22

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About ProQR Therapeutics N.V.

ProQR Therapeutics NV is a biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis, or CF.

Sector

Healthcare

Industry

Biotechnology